Skip to content
Clinical Trials – home

Exenatide: A Comprehensive Guide for Patients

4 / 6
trials open to patients / all trials
6+
Countries

In short

Exenatide, also known as AC2993 or synthetic exendin-4, is a drug being studied in clinical trials for the treatment of type 2 diabetes mellitus. These trials aim to assess its effects on glucose control, body weight, and overall safety when used alone or in combination with other diabetes medications. The studies involve various dosages and administration methods to determine the optimal use of exenatide in managing diabetes.

At a glance

Drug Name
Exenatide (AC2993, synthetic exendin-4)
Condition Studied
Type 2 Diabetes Mellitus
Administration
Subcutaneous injection, typically twice daily
Dosages
2.5 mcg, 5 mcg, 10 mcg
Primary Outcomes
Changes in HbA1c, fasting plasma glucose, body weight
Study Duration
Varies, up to 52 weeks in some trials
Combination Therapies
Studied with metformin and/or sulfonylureas
Special Populations
Includes studies on adolescents and different ethnic groups (e.g., South Asians)
Additional Research
Effects on brown adipose tissue and energy expenditure

What is Exenatide?

Exenatide is a medication used primarily in the treatment of type 2 diabetes mellitus. It belongs to a class of drugs called GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). Exenatide is also known by its brand names Byetta and Bydureon, and in some clinical trials, it's referred to as AC2993 or synthetic exendin-4.

What Conditions Does Exenatide Treat?

Exenatide is primarily used to treat:

  • Type 2 Diabetes Mellitus: This is the main condition for which exenatide is prescribed. It helps control blood sugar levels in adults with type 2 diabetes.
  • Chronic Kidney Disease: Some studies are investigating its potential benefits in patients with type 4 cardiorenal syndrome, which involves both heart and kidney issues.
  • Left Ventricular Diastolic Dysfunction: This is a condition where the heart's left ventricle doesn't relax properly between beats. Research is exploring exenatide's effects on this condition.

How Does Exenatide Work?

Exenatide works by mimicking a hormone called GLP-1 (glucagon-like peptide-1) in your body. Here's how it helps:

  • Stimulates insulin production: It encourages your pancreas to release more insulin when your blood sugar levels are high. Insulin helps move sugar from your blood into your cells.
  • Reduces glucagon: Exenatide decreases the amount of glucagon in your body. Glucagon is a hormone that raises blood sugar levels.
  • Slows digestion: It can slow down the emptying of your stomach, which helps control how quickly sugar enters your bloodstream after eating.
  • Promotes weight loss: Many patients experience weight loss while taking exenatide, which can be beneficial for managing diabetes.

How is Exenatide Administered?

Exenatide is administered through subcutaneous injection. This means it's injected just under the skin, typically in the thigh, abdomen, or upper arm. There are two main forms of exenatide:

  • Immediate-release (Byetta): This is typically injected twice daily, before morning and evening meals.
  • Extended-release (Bydureon): This is a long-acting form that is injected once weekly.

Dosage Information

The dosage of exenatide can vary depending on the specific formulation and individual patient needs. Here are some general guidelines based on the clinical trials:

  • Immediate-release (Byetta):
    • Starting dose: 5 μg (micrograms) twice daily for 4 weeks
    • Maintenance dose: May be increased to 10 μg twice daily if needed and tolerated
  • Extended-release (Bydureon):
    • Typically 2 mg injected once per week

Always follow your doctor's instructions regarding dosage, as they may adjust it based on your individual response and needs.

Effectiveness of Exenatide

Clinical trials have shown that exenatide can be effective in managing type 2 diabetes. Its effectiveness is often measured by changes in HbA1c levels, which reflect average blood sugar levels over the past 2-3 months. Some key findings include:

  • Improved blood sugar control: Studies have shown significant reductions in HbA1c levels in patients taking exenatide compared to placebo.
  • Weight loss: Many patients experience weight loss while taking exenatide, which can be beneficial for managing diabetes.
  • Combination therapy: Exenatide has been shown to be effective when used alone or in combination with other diabetes medications like metformin or sulfonylureas.

Potential Side Effects

Like all medications, exenatide can cause side effects. Some potential side effects include:

  • Gastrointestinal issues: Nausea, vomiting, and diarrhea are common, especially when first starting the medication.
  • Hypoglycemia: When used with certain other diabetes medications, there may be an increased risk of low blood sugar.
  • Injection site reactions: Some people may experience redness, itching, or swelling at the injection site.

Always discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking exenatide.

Ongoing Research

Researchers continue to study exenatide to understand its full potential. Some areas of ongoing research include:

  • Cardiorenal syndrome: Investigating its effects on heart and kidney function in patients with type 4 cardiorenal syndrome.
  • Hypoglycemia awareness: Studying whether exenatide can improve awareness of low blood sugar episodes in patients with type 1 diabetes.
  • Brown adipose tissue: Exploring its potential effects on brown fat activity and energy expenditure.

These ongoing studies may lead to new uses for exenatide or provide more information about its long-term effects and benefits.

Questions people often ask

Conditions where Exenatide is being studied

Each condition opens its own overview and trial list

Trials with Exenatide

Recruiting trials first

See all 6 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).